Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia

American Journal of Health-System Pharmacy

Volumn 60, Issue 14, 2003, Pages 1426-1439

  Lee, Mary ^a  

^a Chicago College of Pharmacy   (United States)

Author keywords

Alfuzosin hydrochloride; Blood levels; Dosage; Dosage schedules; Mechanism of action; Pharmacokinetics; Prostatic hyperplasia; Quality of life; Sustained action medications; Sympatholytic agents; Toxicity

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; FINASTERIDE; QUINAZOLINE DERIVATIVE;

CARDIOVASCULAR DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; CLINICAL TRIAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG COMBINATION; DRUG INTERACTION; MALE;

ADRENERGIC ALPHA-ANTAGONISTS; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FINASTERIDE; HUMANS; MALE; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUINAZOLINES;

EID: 0142089738     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.14.1426     Document Type: Review

References (94)

1. Berry SJ, Coffey DS, Walsh PC et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984; 132:474-9.
2. Schlegel PN. Medical management of prostatic diseases. Adv Intern Med. 1994; 39:569-601.
3. Isaacs JT. Epidemiology and natural history of benign prostatic hyperplasia. In: Caine M, ed. Prostate and alpha-blockers. Almere, Netherlands: Excerpta Medica; 1989:219-30.
4. Cooper KL, McKiernan JM, Kaplan SA. Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs. 1999; 57:9-17.
5. 1 blockers for BPH: are there differences? Eur Urol. 1999; 36(suppl 3):52-63.
6. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol. 1975; 47:193-202.
7. 1 adrenergic receptor subtypes in human prostate. J Urol. 1993; 150:546-51.
8. 1 adrenoceptors and uroselectivity. Prostate. 1997; 30:202-15.
9. Parfitt K, ed. Martindale the complete drug reference. 32nd ed. London: Pharmaceutical Press; 1999:833.
10. 1 adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study. Eur J Pharmacol. 1994; 261:59-64.
11. Caine M, Perlberg S, Shapiro A. Phenoxybenzamine for benign prostatic obstruction. Review of 200 cases. Urology. 1981; 17:542-6.
12. Abrams PH, Shah PJ, Stone R et al. Bladder outflow obstruction titrated with phenoxybenzamine. Br J Urol. 1982; 54:527-30.
13. Perissin L, Rapozzi V, Zorzet S et al. Blockers of adrenergic neurons and receptors, tumor progression and effects of rotational stress in mice. Anticancer Res. 1996; 16:3409-13.
14. Akduman B, Crawford ED. Terazosin, doxazosin, and prazosin: current clinical experience. Urology. 2001; 58(6, suppl 1):49-54.
15. Martin DJ, Angel I, Arbilla S. Functional uroselectivity. Eur Urol. 1998; 33 (suppl 2):12-8.
16. Michel MC, Flannery MT, Narayan P. Worldwide experience with alfuzosin and tamsulosin. Urology. 2001; 58:508-16.
17. 1-adrenoceptor selectivity? Br J Urol. 1995; 76(suppl 1):47-55.
18. 1D adrenoceptor subtypes. Br J Pharmacol. 1997; 120:231-8.
19. 1 adrenoceptor antagonist binding in human prostate and aorta. Clin Exp Pharmacol Physiol. 1994; 21:405-11.
20. De Mey C. Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being. Eur Urol. 1998; 34(suppl 2):18-28.
21. 1 adrenoreceptor antagonist in the lower urinary tract. Br J Pharmacol. 1993; 109:1282-9.
22. Lefevre-Borg F, Lechaire J, O'Connor S. In vivo uroselectivity of alfuzosin compared to prazosin and terazosin. Br J Pharmacol. 1992; 106(suppl):84.
23. Wilde MI, Fitton A, McTavish D. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993; 45:410-29.
24. Scott MG, Deering AH, McMahon MT et al. Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose-ranging study and comparison with prazosin. Eur J Clin Pharmacol. 1989; 37:53-8.
25. Teillac P, Delauche-Cavallier MC, Attali P. Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. Br J Urol. 1992; 70:58-64.
26. Salva P, Bianchetti G, Morselli P et al. Pharmacokinetics of alfuzosin after single oral administration to healthy volunteers, of three different doses. Biopharm Drug Dispos. 1992; 13:583-90.
27. Van Kerrebroeck PE. The efficacy and safety of a new once-a-day formulation of an α blocker. Eur Urol. 2001; 39(suppl 6):19-26.
28. Rauch C, Andre F, Therot JP et al. Bioequivalence study of a new once-a-day controlled release alfuzosin formulation with the 5-mg twice daily formulation. J Urol. 2000; (163 suppl):306. Abstract.
29. Rauch C, Ahtoy P, Pinquier JL et al. Bioequivalence of a new once-a-day controlled-release alfuzosin formulation with the immediate-release alfuzosin. Eur J Urol. 2000; (37 suppl 2):119. Abstract.
30. Van Kerrebroeck PE, Jardin A, Laval KU et al. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol. 2000; 37:306-13.
31. Monda JM, Oesterling JE. Medical treatment of benign prostatic hyperplasia: 5α reductase inhibitors and α adrenergic antagonists. Mayo Clin Proc. 1993; 68:670-9.
32. Roehrborn CG. The Agency for Health Care Policy and Research. Clinical guidelines for the diagnosis and treatment of benign prostatic hyperplasia. Urol Clin North Am. 1995; 22:445-53
33. 1 adrenoceptor subtype-specific blockade. Br J Urol. 1998; 81(suppl 1):34-47.
34. Eri LM, Tveter KJ. Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective. Drugs Aging. 1997; 10:107-18
35. 1 blocker therapy for lower urinary track symptoms suggestive of benign prostatic obstruction: what are the relevant differences in randomised controlled trials? Eur Urol. 2000; 38(suppl 1):25-39.
36. 1 adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999; 36:1-13.
37. Lukacs B. Using a large clinical database to assess the effectiveness of alfuzosin. Eur Urol. 1997; 32(suppl 2):45-7.
38. Hofner K, Claes H, DeReijke TM et al. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999; 36:335-41.
39. 1 blocker vs 5α reductase inhibitors in benign prostatic hyperplasia. A comparative review. Drugs Aging. 1995; 6:388-96.
40. Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate Suppl. 1990; 3:1-7.
41. Jardin A, Bensadoun H, Delauche-Cavallier MC et al. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet. 1991; 337:1457-61.
42. Hansen BJ, Nordling J, Mensink HJ et al. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. Scand J Urol Nephrol Suppl. 1994; 157:169-76.
43. Hansen BJ, Flyger H, Mortensen S et al. Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the Danish Prostatic Symptom Score (DAN-PSS-1) system. Scan J Urol Nephrol. 1996; 30:103-7.
44. Carbin BE, Bauer P, Friskand M et al. Efficacy of alfuzosin (an alpha 1-adrenoreceptor blocking drug) in benign prostatic hyperplasia of the prostate. Scan J Urol Nephrol Suppl. 1991; 138:73-5.
45. Schulman CC, De Sy W, Vandendris M et al. Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. Acta Urol Belg. 1994; 62:15-21.
46. 1 blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. Eur Urol. 1997; 32:47-53.
47. Buzelin JM, Delauche-Cavallier MC, Roth S et al. Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Br J Urol. 1997; 79:898-904.
48. Buzelin JM, Roth S, Geffriaud-Ricouard C et al. Efficacy and safety of sustained release alfuzosin 5 mg in patients with benign prostatic hyperplasia. Eur Urol. 1997; 31:190-8.
49. McNeill SA, Hargreave TB, Geffriaud-Ricouard C et al. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven con trolled studies with alfuzosin. Urology. 2001; 57:459-65.
50. McNeill SA, Daruwala PD, Mitchell ID et al. Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled trial. BJU Int. 1999; 84:622-7.
51. McNeill SA. Does acute urinary retention respond to alpha-blockers alone? Eur Urol. 2001; 39(suppl 6):7-12.
52. Lukacs B, Grange JC, Comet D et al. History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. Eur Urol. 2000; 37:183-90.
53. Jardin A, Bensadoun H, Delauche-Cavallier C et al. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month assessment. Br J Urol. 1994; 74:579-84.
54. Lukacs B, Blondin P, MacCarthy C et al. Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Eur Urol. 1996; 29:29-35.
55. Buzelin JM, Hebert M, Blondin P et al. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. Br J Urol 1993; 72:922-7.
56. Buzelin JM, Fonteyne E, Kontturi M et al. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol. 1997; 80:597-605.
57. The Italian Alfuzosin Cooperative Group. Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patient's quality of life. Eur Urol. 1995; 27:128-34.
58. Mebust WK, Ackerman R, Barry MJ et al. Symptom evaluation, quality of life and sexuality. In: Cockett AT, Khoury S, Aso Y et al., eds. Proceedings of the Third International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey, Channel Islands: Scientific Communications International; 1998:257-61.
59. McConnell JD, Barry MJ, Bruskewitz RC et al. Benign prostatic hyperplasia: diagnosis and treatment. Clinical practice guideline, no. 8. Rockville, MD: U.S. Department of Health and Human Services, 1994; AHCPR publication no. 94-0582.
60. Vela Navarrete R, Martin Morena JM, Calahorra FJ et al. [Cultural and linguistic validation in Spanish of the International Prostatic Symptoms-Scale (I-PSS).] Actas Urol Esp. 1994; 18:841-7. In Spanish.
61. Fowler FJ Jr, Wennberg JE, Timothy RP et al. Symptom status and quality of life following prostatectomy. JAMA. 1988; 259:3018-22.
62. Lukacs B, LePlege A, McCarthy C et al. Construction and validation of a BPH-specific health related quality of life scale (with special attention to sexuality) for medical outcome research: In:Cockett AT, Khoury S, Aso Y et al., eds. Proceedings of the Second International Consultation on Benign Prostatic Hyperplasia (BPH). Paris: Scientific Communications International; 1994:139-45.
63. 1 blocker alfuzosin in symptomatic patients with BPH. Eur Urol. 2000; 37:680-6.
64. Sanchez-Chapado M, Guil M, Alfaro V et al. Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice. Eur Urol. 2000; 37:421-7.
65. Lukacs B, Grange JC, Comet D et al. Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in general practice. Prostate Cancer Prostate Dis. 1998; 1:276-93.
66. Lukacs B, Leplege A, Thibault P et al. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology. 1996; 48:731-40.
67. Martelli A, Pacifico P, Casadei G. Effect of alfuzosin on quality of life in benign prostatic hyperplasia patients: preliminary results. Eur Urol. 1993; 24(suppl 1):28-33.
68. Lepor H, Williford WO, Barry MJ et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 1996; 335:533-9.
69. Debruyne FM, Jardin A, Colloi D et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol. 1998; 34:169-75.
70. 1 adrenoceptor blocker in essential hypertension. Eur J Clin Pharmacol. 1988; 35:25-30.
71. Sanchez-Chapado M, Guil M, Badiella LI et al. The clinical uroselectiviry of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. BJU Int. 2000; 86:432-8.
72. Kirby RS. Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia. Eur Urol. 1998; 33(suppl 2):19-27.
73. Ottervanger JP, Wilson JH, Stricker BH. Drug-induced chest pain and myocardial infarction. Reports to a national centre and review of the literature. Eur J Clin Pharmacol. 1997; 53:105-10.
74. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000; 283:1967-75.
75. Roehrborn CG. The newly established guidelines for the diagnosis and management of benign prostatic hyperplasia. Curr Opin Urol. 1995; 5:30-4.
76. Kedia KR, Persky L. Effect of phenoxybenzamine (dibenzyline) on sexual function in man. Urology. 1981; 18:620-1.
77. Seo KK, Lee MY, Lim SW et al. Comparison of relaxation responses of cavernous and trigonal smooth muscles from rabbits by alpha-1-adrenoceptor antagonists: prazosin, terazosin, doxazosin, and tamsulosin. J Korean Med Sci. 1999; 14:69-74.
78. Vela-Casasempere P, Borras-Blasco J, Navarro-Ruiz A. Alfuzosin-associated dermatomyositis. Br J Rheumatol. 1998; 37:1135-6.
79. Navarro-Blasco FJ. Alfuzosin is not associated with dermatomyositis. Rheumatology. 1999; 38:579. Letter.
80. Zabala S, Thomson C, Valdearcos S et al. Alfuzosin-induced hepatotoxicity. J Clin Pharm Ther. 2000; 25:73-4.
81. Bianchetti G, Padovani P, Coupez JM et al. Pharmacokinetic interaction between hydrochlorothiazide, atenolol and alfuzosin: a new antihypertensive drug. Acta Pharmacol Toxicol. 1986; 59(suppl 5):197-205.
82. Hansten PD, Horn JR. Drug interactions analysis and management. St. Louis: Facts and Comparisons; 2001:176,584A,929.
83. Elliott HL, McLean K, Sumner DJ et al. Immediate cardiovascular responses to oral prazosin-effects of concurrent beta-blockers. Clin Pharmacol Ther. 1981; 29:303-9.
84. Buzelin JM, Geffriaud-Ricouard C, Delauche-Cavallier MC et al. A double-blind placebo-controlled trial of the efficacy and safety of sustained-release alfuzosin in symptomatic benign prostatic hyperplasia. J Urol. 1995; 153 (suppl):274A. Abstract.
85. Jonler M, Riehmann M, Bruskewitz RC. Benign prostatic hyperplasia. Current pharmacological treatment. Drugs. 1994; 47:66-81.
86. Lieber MM. Pharmacologic therapy for prostatism. Mayo Clin Proc. 1998; 73:590-6.
87. Roehrborn CG. Meta-analysis of randomized clinical trials of finasteride. Urology. 1998; 51(suppl 4a):46-9.
88. Tewari A, Narayan P. Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: interactions with antihypertensive therapy. Urology. 1999; 53(suppl 3A):14-20.
89. Kaplan SA, D'Alisera PM. Tolerability of α-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double-blind placebo-controlled studies. J Gerontol A Biol Sci Med Sci. 1998; 53:M201-6.
90. Clifford GM, Farmer RD. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol. 2000; 38:2-19.
91. Monane M, Bohn RL, Gurwitz JH et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens. 1997; 10:697-704.
92. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl. 1995; 168:7-12.
93. Souverein PC, Herings RM, De la Rosette JJ et al. Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations. J Clin Epidemiol. 2001; 54:518-24.
94. Siegal D, Lopez J. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? JAMA. 1997; 278:1745-8.